biostudies-literatureXu SCuiying Scientific and Technological Innovation Program of The Second Hospital & Clinical Medical School, Lanzhou UniversityHigher Education Innovation Fund project and of Gansu Province691https://www.ebi.ac.uk/biostudies/studies/S-EPMC12297935biostudies-literatureUnknown13(7)<b>Background/Objectives</b>: Bovine viral diarrhea virus (BVDV) causes significant economic losses in the cattle industry worldwide. The current vaccines have limited efficacy against diverse BVDV genotypes. Currently, multi-antigen target design and nanocarrier display technologies can provide ideas for broad-spectrum and efficient BVDV vaccine design. <b>Methods</b>: Here we developed a trivalent mRNA vaccine encoding the domains I-II of envelope glycoprotein E2 from three BVDV genotypes (3E2), introduced with bovine IgG1 Fc (bFc), STABILON (hStab), and artificial virus-like particle (ARVLP) containing CD80 transmembrane (TM) domain, FcγRII cytoplasmic domain, and WW domain of ITCH. Then, in vitro expression, in vivo immunogenicity and neutralizing antibody analysis were performed to evVaccinesA Novel Trivalent BVDV mRNA Vaccine Displayed by Virus-like Particles Eliciting Potent and Broad-Spectrum Antibody Responses.PMC12297935CY2023-MS-B182025B-23Li JXu MFei CWang AGeng WLiu RLiu SChen HHe QHan TRuan KQian YXu SCai YGao XfalseA Novel Trivalent BVDV mRNA Vaccine Displayed by Virus-like Particles Eliciting Potent and Broad-Spectrum Antibody Responses.<b>Background/Objectives</b>: Bovine viral diarrhea virus (BVDV) causes significant economic losses in the cattle industry worldwide. The current vaccines have limited efficacy against diverse BVDV genotypes. Currently, multi-antigen target design and nanocarrier display technologies can provide ideas for broad-spectrum and efficient BVDV vaccine design. <b>Methods</b>: Here we developed a trivalent mRNA vaccine encoding the domains I-II of envelope glycoprotein E2 from three BVDV genotypes (3E2), introduced with bovine IgG1 Fc (bFc), STABILON (hStab), and artificial virus-like particle (ARVLP) containing CD80 transmembrane (TM) domain, FcγRII cytoplasmic domain, and WW domain of ITCH. Then, in vitro expression, in vivo immunogenicity and neutralizing antibody analysis were performed to ev2025-01-01T00:00:00Z2025 Jun2025-08-16T03:06:55.981Z2025-08-16T03:06:55.981ZS-EPMC122979354073366810.3390/vaccines13070691